A 67-year-old man with a history of COPD presents with worsening dyspnoea, leg swelling and orthopnoea. Echocardiography shows LVEF 30%. He is already on maximally tolerated ACE inhibitor, beta blocker and SGLT2 inhibitor. According to heart failure guidelines, which additional agent provides mortality benefit in symptomatic HFrEF?